Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Voorraadrapport

Marktkapitalisatie: US$1.6b

Rocket Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Rocket Pharmaceuticals' is Gaurav Shah, benoemd in Jan2018, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.01M, bestaande uit 7.8% salaris en 92.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.24% van de aandelen van het bedrijf, ter waarde $ 20.77M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.1 jaar en 6.8 jaar.

Belangrijke informatie

Gaurav Shah

Algemeen directeur

US$8.0m

Totale compensatie

Percentage CEO-salaris7.8%
Dienstverband CEO6.8yrs
Eigendom CEO1.2%
Management gemiddelde ambtstermijn3.1yrs
Gemiddelde ambtstermijn bestuur6.8yrs

Recente managementupdates

Recent updates

Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Sep 23
Will Rocket Pharmaceuticals (NASDAQ:RCKT) Spend Its Cash Wisely?

Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review

Sep 15

Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix

Jun 28

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Jun 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)

Apr 05

Rocket Pharmaceuticals' Promising Path In Gene Therapy

Mar 01

Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Nov 07
Companies Like Rocket Pharmaceuticals (NASDAQ:RCKT) Are In A Position To Invest In Growth

Rocket Pharmaceuticals slides over 6% after hours on $100M stock offering

Oct 03

Rocket Pharmaceuticals: Updates To Thesis, Clinical Momentum Continues To Accelerate

Aug 25

We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Jul 22
We're Not Very Worried About Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Rate

Rocket Pharmaceuticals an outperform at Raymond James on gene therapy programs

Jul 08

Rocket Pharma: Poised For Growth In The Rare Disease Space

Jun 30

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Jan 30

We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Nov 09
We're Hopeful That Rocket Pharmaceuticals (NASDAQ:RCKT) Will Use Its Cash Wisely

Rocket Pharmaceuticals Stock Forecast: Can It Rebound To $50 Levels? A Resounding Yes

Oct 01

Rocket earns Evercore nod after positive data for rare genetic disease

Dec 17

Rocket Pharma +33.6% after positive early data in Danon disease Phase 1 trial

Dec 09

Analyse CEO-vergoeding

Hoe is Gaurav Shah's beloning veranderd ten opzichte van Rocket Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$253m

Mar 31 2024n/an/a

-US$249m

Dec 31 2023US$8mUS$625k

-US$246m

Sep 30 2023n/an/a

-US$253m

Jun 30 2023n/an/a

-US$249m

Mar 31 2023n/an/a

-US$237m

Dec 31 2022US$7mUS$598k

-US$222m

Sep 30 2022n/an/a

-US$199m

Jun 30 2022n/an/a

-US$192m

Mar 31 2022n/an/a

-US$172m

Dec 31 2021US$8mUS$590k

-US$169m

Sep 30 2021n/an/a

-US$186m

Jun 30 2021n/an/a

-US$165m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$540k

-US$140m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$89m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$4mUS$480k

-US$77m

Sep 30 2019n/an/a

-US$85m

Jun 30 2019n/an/a

-US$82m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$6mUS$414k

-US$75m

Compensatie versus markt: De totale vergoeding ($USD 8.01M ) Gaurav } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Gaurav is gestegen terwijl het bedrijf verliesgevend is.


CEO

Gaurav Shah (49 yo)

6.8yrs

Tenure

US$8,013,553

Compensatie

Dr. Gaurav D. Shah, M.D., has been an Independent Director at Talaris Therapeutics, Inc. since December 2020. He serves as the Chief Executive Officer and Director of Rocket Pharmaceuticals, Ltd since Janu...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Gaurav Shah
CEO & Director6.8yrsUS$8.01m1.24%
$ 19.7m
Kinnari Patel
Head of R&D6.8yrsUS$4.85m0.44%
$ 7.0m
Mayo Pujols
Chief Technical Officer2.3yrsUS$4.38m0.062%
$ 990.4k
Jonathan Schwartz
Chief Medical & Gene Therapy Officer6.8yrsUS$3.16m0.11%
$ 1.7m
Aaron Ondrey
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Martin Wilson
General Counsel2.9yrsUS$1.56m0.071%
$ 1.1m
Kevin Giordano
Director of Corporate Communicationsno datageen gegevensgeen gegevens
Isabel Carmona
Chief People Officer3.1yrsgeen gegevensgeen gegevens
Gayatri Rao
Senior VP of Clinical Safety & Chief Regulatory Officer4.5yrsgeen gegevensgeen gegevens
Raj Prabhakar
Chief Business Officerno dataUS$2.82m0%
$ 0
Carlos Martin
Chief Commercial Operations & Revenue Officerless than a yeargeen gegevensgeen gegevens

3.1yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RCKT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Gaurav Shah
CEO & Director6.8yrsUS$8.01m1.24%
$ 19.7m
David Southwell
Independent Director10.2yrsUS$399.99k0.13%
$ 2.0m
Pedro Granadillo
Independent Director6.8yrsUS$429.98k0%
$ 0
Carsten Boess
Independent Director8.8yrsUS$427.49k0%
$ 0
Mikael Dolsten
Independent Directorless than a yeargeen gegevensgeen gegevens
Roderick Tze Wong
Chairman of the Board6.8yrsUS$409.99k0.059%
$ 937.8k
Naveen Yalamanchi
Independent Director6.8yrsUS$417.49k0.13%
$ 2.0m
Fady Malik
Independent Non-Executive Director2.6yrsUS$399.99k0%
$ 0
Elisabeth Bjork
Independent Director4.5yrsUS$409.99k0%
$ 0
Gotham Makker
Director6.8yrsUS$399.99k0.22%
$ 3.5m
Robert Woods
Independent Non- Executive Directorless than a yearUS$568.70kgeen gegevens

6.8yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RCKT wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).